These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34048913)

  • 1. Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.
    Magaraggia I; Kuiperes Z; Schreiber R
    Neurobiol Learn Mem; 2021 Sep; 183():107467. PubMed ID: 34048913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.
    Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS
    Psychiatry Res; 2022 Jul; 313():114577. PubMed ID: 35580433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
    Kozlowska U; Nichols C; Wiatr K; Figiel M
    J Neurochem; 2022 Jul; 162(1):89-108. PubMed ID: 34519052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
    van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
    Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibrinolytic system: A new target for treatment of depression with psychedelics.
    Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
    Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beating pain with psychedelics: Matter over mind?
    Elman I; Pustilnik A; Borsook D
    Neurosci Biobehav Rev; 2022 Mar; 134():104482. PubMed ID: 34922987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.
    Mertens LJ; Wall MB; Roseman L; Demetriou L; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2020 Feb; 34(2):167-180. PubMed ID: 31941394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.
    Pouyan N; Halvaei Khankahdani Z; Younesi Sisi F; Lee Y; Rosenblat JD; Teopiz KM; Lui LMW; Subramaniapillai M; Lin K; Nasri F; Rodrigues N; Gill H; Lipsitz O; Cao B; Ho R; Castle D; McIntyre RS
    CNS Drugs; 2022 Oct; 36(10):1031-1047. PubMed ID: 36097251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern Separation: A Potential Marker of Impaired Hippocampal Adult Neurogenesis in Major Depressive Disorder.
    Gandy K; Kim S; Sharp C; Dindo L; Maletic-Savatic M; Calarge C
    Front Neurosci; 2017; 11():571. PubMed ID: 29123464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey.
    Oikonomidis L; Santangelo AM; Shiba Y; Clarke FH; Robbins TW; Roberts AC
    Dev Neurobiol; 2017 Mar; 77(3):328-353. PubMed ID: 27589556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data?
    Puryear CB; Brooks J; Tan L; Smith K; Li Y; Cunningham J; Todtenkopf MS; Dean RL; Sanchez C
    Neurosci Biobehav Rev; 2020 Jan; 108():658-678. PubMed ID: 31821832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of Functional Neuroimaging of Major Depressive Disorder in Youth.
    Miller CH; Hamilton JP; Sacchet MD; Gotlib IH
    JAMA Psychiatry; 2015 Oct; 72(10):1045-53. PubMed ID: 26332700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurogenesis and antidepressant action.
    Park SC
    Cell Tissue Res; 2019 Jul; 377(1):95-106. PubMed ID: 31165247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
    Agin-Liebes G; Davis AK
    Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder.
    Young CB; Chen T; Nusslock R; Keller J; Schatzberg AF; Menon V
    Transl Psychiatry; 2016 May; 6(5):e810. PubMed ID: 27187232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
    Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
    Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.